Long-Term Outcomes of Balloon TACE for HCC: An European Multicentre Single-Arm Retrospective Study.

Pierleone LucatelliBianca RoccoThierry De BeareGontran VersetFabio FucilliElio DamatoAlexandro PaccapeloLorenzo BraccischiMakoto Taninokuchi TomassoniAna-Maria BucalauCarlo CatalanoCristina Mosconi

Published in: Cardiovascular and interventional radiology (2024)

bTACE demonstrated high efficacy for HCC, with a complete response in 58.9% of patients, a median local recurrence-free survival of 31.0 months and a mean overall survival of 50.0 months.

Keyphrases

free survival
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
clinical trial
prognostic factors
study protocol
randomized controlled trial
patient reported outcomes
patient reported